+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Human Insulin Drugs Market in Brazil by Distribution Channel, Product, and Application - Forecast and Analysis 2019-2023 - Product Image

Human Insulin Drugs Market in Brazil by Distribution Channel, Product, and Application - Forecast and Analysis 2019-2023

  • ID: 4856384
  • Report
  • October 2019
  • Region: Brazil
  • 135 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.
  • MORE
Human Insulin Drugs Market in Brazil: About this market
The human insulin drugs market in brazil market analysis considers sales from basal insulin analog and NPH products. Our study also finds the sales of the human insulin drugs market in brazil in retail and hospital distribution channels. In 2018, the basal insulin analog segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as flexibility of timing and dosing, less fear of dose adjustment, and fewer injections with analogs to achieve their therapeutic effect will play a significant role in the basal insulin analog segment to maintain its market position. Also, our human insulin drugs market in brazil report looks at factors such as rising prevalence of diabetes in Brazil, demographic transition in Brazil, and strategic alliance. However, high cost of human insulin drugs, unknown etiology of type I diabetes, and unavailability of specific biomarkers may hamper the growth of the human insulin drugs market in brazil over the forecast period.

Human Insulin Drugs Market in Brazil: Overview

Demographic transition in brazil
Brazil has undergone rapid demographic, nutritional, and epidemiological transitions, which have led to an increase in the prevalence of diabetes in this region. Currently, the youth demographic forms a significant portion of Brazil’s population. Since type I diabetes affects an individual at an incredibly young age, the presence of a large younger demographic provides significant growth opportunities for vendors in the human insulin drugs market in Brazil. This demographic transition in brazil will lead to the expansion of the human insulin drugs market in brazil at a CAGR of over 5% during the forecast period.

Technological advancements
Technological advancements are expected to be one of the key factors for the growth of the human insulin drug market size in Brazil during the forecast period. The availability of novel digital equipment and data-driven devices, such as the connected care insulin delivery system, has fueled the interest of researchers in this area. The major vendors in the market are now focusing on developing novel human insulin drugs through strategic alliances, especially by partnering with research institutes and other healthcare organizations. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the human insulin drugs market in brazil is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human insulin drugs market in brazil manufacturers, that include Biocon Ltd., Eli Lilly and Co., Novo Nordisk AS, Sanofi, and Wockhardt Ltd.

Also, the human insulin drugs market in brazil includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: INSULIN: AN OVERVIEW

PART 07: MARKET SEGMENTATION BY DISTRIBUTION CHANNEL
  • Market segmentation by distribution channel
  • Comparison by distribution channel
  • Retail - Market size and forecast 2018-2023
  • Hospitals - Market size and forecast 2018-2023
  • Market opportunity by distribution channel
PART 08: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Basal insulin analog - Market size and forecast 2018-2023
  • NPH - Market size and forecast 2018-2023
  • Market opportunity by product
PART 09: CUSTOMER LANDSCAPE

PART 10: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Type I diabetes - Market size and forecast 2018-2023
  • Type II diabetes - Market size and forecast 2018-2023
  • Market opportunity by application
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Advent of biosimilars
  • Increasing initiatives by vendors
  • Technological advancements
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.
PART 16: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Country market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Health finance indicator in Brazil (1995-2011)
Exhibit 10: Timeline of Brazil’s unified health system
Exhibit 11: Country market: Year-over-year growth 2019-2023 (%)
Exhibit 12: Five forces analysis 2018
Exhibit 13: Five forces analysis 2023
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition - Five forces 2018
Exhibit 20: Blood glucose control
Exhibit 21: Types of human insulin analog
Exhibit 22: Distribution channel - Market share 2018-2023 (%)
Exhibit 23: Comparison by distribution channel
Exhibit 24: Retail - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Retail - Year-over-year growth 2019-2023 (%)
Exhibit 26: Hospitals - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Unified Health System and funding channels in Brazil
Exhibit 28: Hospitals - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by distribution channel
Exhibit 30: Product - Market share 2018-2023 (%)
Exhibit 31: Comparison by product
Exhibit 32: Basal insulin analog - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Basal insulin analog - Year-over-year growth 2019-2023 (%)
Exhibit 34: NPH - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: NPH - Year-over-year growth 2019-2023 (%)
Exhibit 36: Market opportunity by product
Exhibit 37: Customer landscape
Exhibit 38: Application - Market share 2018-2023 (%)
Exhibit 39: Comparison by application
Exhibit 40: Type I diabetes - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: Type I diabetes - Year-over-year growth 2019-2023 (%)
Exhibit 42: Type II diabetes - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: Type II diabetes - Year-over-year growth 2019-2023 (%)
Exhibit 44: Market opportunity by application
Exhibit 45: Mortality by cause (2008)
Exhibit 46: Non-communicable disease-related mortality rate (2008)
Exhibit 47: Demographic indicators in Brazil (1980-2015)
Exhibit 48: Practical phenotypic characteristics used to differentiate between type I and type II diabetes
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: Biocon Ltd. - Vendor overview
Exhibit 56: Biocon Ltd. - Business segments
Exhibit 57: Biocon Ltd. - Organizational developments
Exhibit 58: Biocon Ltd. - Geographic focus
Exhibit 59: Biocon Ltd. - Segment focus
Exhibit 60: Biocon Ltd. - Key offerings
Exhibit 61: Biocon Ltd. - Key customers
Exhibit 62: Eli Lilly and Co. - Vendor overview
Exhibit 63: Eli Lilly and Co. - Product segments
Exhibit 64: Eli Lilly and Co. - Organizational developments
Exhibit 65: Eli Lilly and Co. - Geographic focus
Exhibit 66: Eli Lilly and Co. - Segment focus
Exhibit 67: Eli Lilly and Co. - Key offerings
Exhibit 68: Eli Lilly and Co. - Key customers
Exhibit 69: Novo Nordisk AS - Vendor overview
Exhibit 70: Novo Nordisk AS - Business segments
Exhibit 71: Novo Nordisk AS - Organizational developments
Exhibit 72: Novo Nordisk AS - Geographic focus
Exhibit 73: Novo Nordisk AS - Segment focus
Exhibit 74: Novo Nordisk AS - Key offerings
Exhibit 75: Novo Nordisk AS - Key customers
Exhibit 76: Sanofi - Vendor overview
Exhibit 77: Sanofi - Business segments
Exhibit 78: Sanofi - Organizational developments
Exhibit 79: Sanofi - Geographic focus
Exhibit 80: Sanofi - Segment focus
Exhibit 81: Sanofi - Key offerings
Exhibit 82: Sanofi - Key customers
Exhibit 83: Wockhardt Ltd. - Vendor overview
Exhibit 84: Wockhardt Ltd. - Business segments
Exhibit 85: Wockhardt Ltd. - Organizational developments
Exhibit 86: Wockhardt Ltd. - Geographic focus
Exhibit 87: Wockhardt Ltd. - Key offerings
Exhibit 88: Wockhardt Ltd. - Key customers
Exhibit 89: Validation techniques employed for market sizing
Exhibit 90: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.
  • MORE
The following companies as the key players in the human insulin drugs market in brazil: Biocon Ltd., Eli Lilly and Co., Novo Nordisk AS, Sanofi, and Wockhardt Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the technological advancements.”

According to the report, one of the major drivers for this market is the demographic transition in brazil.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of human insulin drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll